Loading
A phase 1/2 trial of YH42946 in non-small-cell lung cancer, run by Yuhan Corporation, now recruiting.
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 is a phase 1/2 interventional study registered as NCT06616766 by Yuhan Corporation, with 201 participants planned, started 2024-10-02 and due to reach its primary completion in 2028-03-15. Interventions recorded: YH42946.
Shares HER2-mutant non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, EGFR, HER2 and the tag pipeline.
Shares Yuhan Corporation, HER2 and the tag pipeline.
Shares Yuhan Corporation, EGFR and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, HER2, Non-small-cell lung cancer and the tag pipeline.